Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Man, I wish…hope this would lead to something big…but Koos’ actions haven’t instilled much confidence, you know?
I wish I had listened to you 4 years ago, Sid.
This stock is a dog.
-Halp
I’m gonna watch Wolf of Wallstreet…
Yes ‘odd lot’, if you will but a whole number.
My shares were already converted…
Thanks Sid.
I may have misunderstood the original poster’s question re: peer reviewed articles pertaining to Nuclear Receptors/NR2F6 but I was simply pointing out that there are indeed said reputable Journal publications re: this particular receptor.
I would hope for ALL, including investors w/ RGBP, that the patents ‘help’.
-AH
Niu, C.; Sun, X.; Zhang, W.; Li, H.; Xu, L.; Li, J.; Xu, B.; Zhang, Y. NR2F6 Expression Correlates with Pelvic Lymph Node Metastasis and Poor Prognosis in Early-Stage Cervical Cancer. Int. J. Mol. Sci. 2016, 17, 1694. https://doi.org/10.3390/ijms17101694
My sentiments exactly, MT. Thanks.
-Halp
NR2F6 and real possibilities for RGBP patents; this is just one example of how modulation of this particular Nuclear Receptor matters.
Research | 18 April 2018 | OPEN
Nuclear receptor NR2F6 inhibition potentiates responses to PD-L1/PD-1 cancer immune checkpoint blockade
Victoria Klepsch, Natascha Hermann-Kleiter[…]Gottfried Baier
Nature Communications 9 , 1–13
RGBP looks to have strong science behind its patents that hopefully will help many.
Btw, like this article, thanks for letting us know (a few of you alluded to it).
INSIDER FINANCIAL April 10, 2021: "Regen BioPharma About To Become A Major Pharma Player" Quote: What we like about Regen BioPharma is that it is at the same price where we recommended HMBL to our readers and subscribers, which you can read here. HMBL would go on to run to almost $8 from just $.027 a share.......We think RGBP has just as much potential.
(619) 702 1404 (Issuer’s telephone number) listed on the 8-K was NOT IN SERVICE when I called it yesterday. I tried the number on Zander urL and it rolled to generic vm (I did not leave a message); not long after I received a missed call with I.D. "KOOS, DAVID". He did not leave me a vm.
Patents and science are real. Why the faulty phone number on an SEC form? Why the lack of updated home page to properly market strong IP, etc.?? Should we be concerned? Thanks for your input, All.
-Halp
Joe, please see my recent post/reply to Knapper. What do you think?
BTW, I called the number listed on Zander website; it rolled to a generic vm. However, I received a 'missed call' a few minutes later (I was seeing patients and couldn't answer it) from..."KOOS DAVID". Yep. No vm left for me. Not sure what to make of that; the patents and science described there-in appear relatively sound. Inflammation is seemingly omnipresent in Medicine; targeting that and the other conditions noted via RGBP reported patents makes sense. It's just...interesting that genuine patents and SEC filings have occurred which list a company address that may have...changed?
Thoughts?
-Halp
Agreed, Knapper...BUT where is the actual R&D...the lab...the science occurring?
The RGBP website phone number for the office in Mesa is 'not in service'. I find it hard to believe that one could fake SEC filings AND Patents. Your, other's thoughts?
-Halp
Yep. So much in Medicine is about inflammation. This IS significant.
-Halp
Outstanding, thanks for the heads-up. I would think this signifies the company is indeed viable and on the radar for acquisition.
Wish folks would have purchased RGBP instead of GAMESTOP; real and potentially life-saving biomedical patents should matter more...
Hopefully it won't be long now before RGBP's patents can be put to use.
-Halp
............
CCAS journal article
Research
Open Access
Published: 14 January 2020
Targeting the orphan nuclear receptor NR2F6 in T cells primes tumors for immune checkpoint therapy
Victoria Klepsch, Maria Pommermayr, […]Gottfried Baier
Cell Communication and Signaling volume 18, Article number: 8 (2020) Cite this article
When and where is the annual (sharholders) meeting? That should prove...interesting.
"...known as immune checkpoint theory, had "revolutionized cancer treatment and has fundamentally changed the way we view how cancer can be managed," the committee said.
Excerpt from:
CNN) — American James Allison and Japan's Tasuku Honjo have won the 2018 Nobel Prize in Medicine for a pioneering approach to cancer treatment.
The Nobel committee said the pair's research -- which harnesses the body's immune system to attack cancer cells -- amounted to a "landmark in our fight against cancer." The approach, known as immune checkpoint theory, had "revolutionized cancer treatment and has fundamentally changed the way we view how cancer can be managed," the committee said.
Yep, stay the course!
CNN) — American James Allison and Japan's Tasuku Honjo have won the 2018 Nobel Prize in Medicine for a pioneering approach to cancer treatment.
The Nobel committee said the pair's research -- which harnesses the body's immune system to attack cancer cells -- amounted to a "landmark in our fight against cancer." The approach, known as immune checkpoint theory, had "revolutionized cancer treatment and has fundamentally changed the way we view how cancer can be managed," the committee said.
Nuclear receptor NR2F6 inhibition potentiates responses to PD-L1/PD-1 cancer immune checkpoint blockade.
Klepsch V, et al. Nat Commun. 2018.
Perhaps POTUS wants to censor this too...
No Toxicity Seen in Mice as Regen BioPharma, Inc. Finishes Initial Optimization of its Lead NR2F6 Small Molecule Agonist
PR Newswire
PR NewswireJuly 23, 2018, 12:37 AM MDT
Establishing lack of toxicity, if you will, is the/an important first step with any 'drug protocol'. Sounds like RGBP has done so. I would anticipate an upward trend in price commensurate w this relatively good news.
-Dr. H.
Sorry, swamped at hospital. Thanks for posting the link! I figured it would be helpful for folks visiting this chat room to 'see' that this IS Science; hopefully RGBP does indeed have legit patents one or two of which will prove effective immunomodulators, if you will.
FYI, All:
Nuclear receptor NR2F6 inhibition potentiates responses to PD-L1/PD-1 cancer immune checkpoint blockade
Victoria Klepsch, Natascha Hermann-Kleiter, […]Gottfried Baier
Nature Communications volume 9, Article number: 1538 (2018)
doi:10.1038/s41467-018-04004-2
-Halp
FYI, All:
Nuclear receptor NR2F6 inhibition potentiates responses to PD-L1/PD-1 cancer immune checkpoint blockade
Victoria Klepsch, Natascha Hermann-Kleiter, […]Gottfried Baier
Nature Communications volume 9, Article number: 1538 (2018)
doi:10.1038/s41467-018-04004-2
-Halp
Well put, J7.
-AH
Perhaps... However, 'NR2F6' immune modulation is a LEGIT area of R&D for neoplastic and autoimmune concerns. Thus, there is a potential HUGE market to be made. RGBP is worth the investment...worth rolling the dice IMO.
-AH
Physician
As a board certified physician, I concur...well put.
-Halp
Agreed. Patents are there for relatively promising immunotherapy agents. These things take time to develop and gain various approvals or be 'purchased', if you will. Wish the Daytraders/Shorters would lay off!
-Halp (physician)